Stockscreener 앱 받기
135.49
3.03%
3.98
시장 영업 전:
135.22
-0.27
-0.20%
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com UK
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis
Palvella prices $200M stock offering at $125 per share - Investing.com Australia
Strategic Update: PVLA Surges Amid New Growth Plans - timothysykes.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade - MarketBeat
Palvella Therapeutics shares rise to three-year high on upsized offering - Investing.com UK
Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - simplywall.st
What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat
HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews
Palvella Therapeutics announces pricing of upsized public offering - marketscreener.com
Palvella Therapeutics Announces Pricing of Upsized Public Offering - Bitget
Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance
BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat
Palvella launches $150M public stock offering - Investing.com India
Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin - MarketBeat
Aug Big Picture: Is Innovative Solutions and Support Inc showing insider buyingPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Palvella Therapeutics announces proposed public offering - marketscreener.com
Palvella Therapeutics Launches $150 Million Public Offering - marketscreener.com
Palvella Therapeutics Stock Takes a Dive Amidst Market Flux - timothysykes.com
Palvella Therapeutics stock hits 52-week high at 115.95 USD By Investing.com - Investing.com South Africa
Palvella launches $150M public stock offering By Investing.com - Investing.com UK
Palvella Therapeutics Announces Proposed Public Offering - The Manila Times
Why Top 2% Palvella Therapeutics, Up 33%, Just Blew Past Its 50-Day Line - Investor's Business Daily
Strategic Acquisition Expands PVLA’s Market Reach in Europe - StocksToTrade
Truist raises Palvella Therapeutics stock price target on phase 3 data - Investing.com Australia
TD Cowen raises Palvella Therapeutics price target on phase 3 data - Investing.com Canada
Chardan Capital Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $210.00 - MarketBeat
Global Pharma Merger: PVLA’s Game-Changer - timothysykes.com
Stifel raises Palvella Therapeutics price target on trial results By Investing.com - Investing.com Canada
Novo to cut GLP-1 drug prices; Palvella soars on study data - BioPharma Dive
Bladder phase II sinks Protara, LMs phase III wins for Palvella - BioWorld MedTech
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighTime to Buy? - MarketBeat
Palvella stock surges on late-stage trial win (PVLA:NASDAQ) - Seeking Alpha
Palvella Therapeutics Up Over 34%, on Track for Highest Close Since March 2023 -- Data Talk - 富途牛牛
Palvella reports positive Phase 3 results for lymphatic malformation gel By Investing.com - Investing.com Nigeria
Palvella Therapeutics stock hits 52-week high at 115.95 USD - Investing.com
Palvella Therapeutics Says Qtorin Meets Primary Endpoint in Phase 3 Study on Microcystic Lymphatic Malformations - marketscreener.com
Palvella reports positive Phase 3 results for lymphatic malformation gel - Investing.com
Palvella Reports Positive Phase 3 Data for QTORIN Gel - TipRanks
Why Did PVLA Stock Surge 45% In Pre-Market Today? - Menafn.com
0.11%
6.00%
자본화:
|
볼륨(24시간):